诺和诺德下一代减肥药受挫

Core Viewpoint - Novo Nordisk's CagriSema did not demonstrate non-inferiority in weight loss effectiveness compared to Eli Lilly's tirzepatide, resulting in a significant drop in Novo Nordisk's stock price while Eli Lilly's stock price increased [1] Group 1 - Novo Nordisk reported that CagriSema's weight loss results were not as effective as those of tirzepatide from Eli Lilly [1] - The announcement led to a substantial decline in Novo Nordisk's stock price [1] - In contrast, Eli Lilly's stock price experienced an increase following the news [1]